Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

被引：0
|
作者：
Pamela Munster
Ian E. Krop
Patricia LoRusso
Cynthia Ma
Barry A. Siegel
Anthony F. Shields
István Molnár
Thomas J. Wickham
Joseph Reynolds
Karen Campbell
Bart S. Hendriks
Bambang S. Adiwijaya
Elena Geretti
Victor Moyo
Kathy D. Miller
机构：
[1] University of California,Helen Diller Family Comprehensive Cancer Center, Department of Medicine
[2] Dana-Farber Cancer Institute,Department of Medical Oncology
[3] Yale Cancer Center,Department of Medicine and the Alvin J. Siteman Cancer Center
[4] Washington University School of Medicine,Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center
[5] Washington University School of Medicine,Department of Oncology, Karmanos Cancer Institute
[6] Wayne State University,Research and Development
[7] Merrimack Pharmaceuticals,undefined
[8] Inc,undefined
[9] Indiana University Melvin and Bren Simon Cancer Center,undefined
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1086 / 1093
页数：7
相关论文
共 50 条
  • [1] Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
    Munster, Pamela
    Krop, Ian E.
    LoRusso, Patricia
    Ma, Cynthia
    Siegel, Barry A.
    Shields, Anthony F.
    Molnar, Istvan
    Wickham, Thomas J.
    Reynolds, Joseph
    Campbell, Karen
    Hendriks, Bart S.
    Adiwijaya, Bambang S.
    Geretti, Elena
    Moyo, Victor
    Miller, Kathy D.
    BRITISH JOURNAL OF CANCER, 2018, 119 (09) : 1086 - 1093
  • [2] A Phase I Study of MM-302, a HER2-targeted Liposomal Doxorubicin, in Patients with Advanced, HER2-Positive Breast Cancer
    Wickham, T.
    Futch, K.
    CANCER RESEARCH, 2012, 72
  • [3] A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer
    Munster, Pamela N.
    Miller, Kathy
    Krop, Ian E.
    Dhindsa, Navreet
    Reynolds, Joe
    Geretti, Elena
    Niyikiza, Clet
    Nielsen, Ulrik
    Hendriks, Bart
    Wickham, Thomas J.
    Moyo, Victor M.
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2-positive (HER2+) breast cancer
    Munster, P.
    Krop, I. E.
    Miller, K.
    Dhindsa, N.
    Niyijiza, C.
    Nielsen, U.
    Odueyungbo, A.
    Rajarethinam, A.
    Marande, M.
    Campbell, K.
    Geretti, E.
    Reynolds, J. G.
    Hendriks, B. S.
    Wickham, T.
    Moyo, V.
    LoRusso, P.
    CANCER RESEARCH, 2013, 73
  • [5] A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+metastatic breast cancer
    LoRusso, Patricia
    Krop, Ian
    Miller, Kathy
    Ma, Cynthia
    Siegel, Barry A.
    Shields, Anthony F.
    Molnar, Istvan
    Wickham, Thomas
    Reynolds, Joseph
    Campbell, Karen
    Hendriks, Bart
    McClure, Ty
    Moyo, Victor
    Munster, Pamela
    CANCER RESEARCH, 2015, 75
  • [6] In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumors
    Geretti, E.
    Espelin, C.
    Adiwijaya, B.
    Coma, S.
    Koncki, Z.
    Sumner, P.
    Dumont, N.
    Garcia, G.
    Bloom, T.
    Janovsky, J.
    Reynolds, J.
    Campbell, K.
    Moyo, V.
    Molnar, I.
    LoRusso, P.
    Krop, I.
    Miller, K.
    Ma, C.
    Munster, P.
    Wickham, T.
    CANCER RESEARCH, 2017, 77
  • [7] MM-302, HER2-targeted liposomal doxorubicin, does not impair cardiomyocyte function in vitro
    Reynolds, Joseph
    Klinz, Stephan
    Leonard, Shannon
    Geretti, Elena
    Lee, Helen
    Eckelhofer, Isabelle
    Gaddy, Daniel
    Hendriks, Bart
    Wickham, Tom
    CANCER RESEARCH, 2011, 71
  • [8] Effect of pre-treatment with cyclophosphamide on MM-302 (HER2-targeted liposomal doxorubicin) deposition in HER2-positive metastatic breast cancer patients assessed by 64Cu-MM-302 PET/CT
    Miller, Kathy
    LoRusso, Patricia M.
    Munster, Pamela
    Krop, Ian
    Ma, Cynthia
    Lee, Helen
    Reynolds, Joe
    Campbell, Karen
    Moyo, Victor
    Hendriks, Bart
    Wickham, Thomas
    Siegel, Barry A.
    Shields, Anthony F.
    CANCER RESEARCH, 2015, 75
  • [9] Quantitative evaluation of HER2-mediated cellular uptake of the HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 suggests potential for treating HER2-intermediate tumors
    Geretti, E.
    Espelin, C.
    Adiwijaya, B.
    Dumont, N.
    Coma, S.
    Koncki, Z.
    Garcia, G.
    Bloom, T.
    Rimkunas, V.
    Reynolds, J.
    Campbell, K.
    Moyo, V.
    Molnar, I.
    Lorusso, P.
    Miller, K.
    Ma, C.
    Krop, I. E.
    Munster, P.
    Wickham, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study
    Li, Yinjuan
    Qi, Lu
    Wang, Yu
    Zhao, Xia
    Lv, Shuzhen
    Feng, Yu
    Liu, Chen
    Li, Pu
    Xiong, Bingjun
    Guo, Yihui
    Lv, Dapeng
    Liu, Yongbo
    Mao, Ting
    Yuan, Keyu
    Cheng, Xiaoqiang
    Li, Yanping
    Wang, Xinghe
    ANTI-CANCER DRUGS, 2023, 34 (06) : 763 - 774
12345